Blumenthal Rosalyn D, Osorio Lou, Hayes Marianne K, Horak Ivan D, Hansen Hans J, Goldenberg David M
Center for Molecular Medicine and Immunology, Garden State Cancer Center, 520 Belleville Avenue, Belleville, NJ 07109, USA.
Cancer Immunol Immunother. 2005 Apr;54(4):315-27. doi: 10.1007/s00262-004-0597-6. Epub 2004 Dec 11.
In addition to its use as a blood marker for many carcinomas, elevated expression of carcinoembryonic antigen (CEA, CD66e, CEACAM5) has been implicated in various biological aspects of neoplasia, especially tumor cell adhesion, metastasis, the blocking of cellular immune mechanisms, and having antiapoptosis functions. However, it is not known if treatment with anti-CEA antibodies can affect tumor metastasis or alter the effects of cytotoxic drugs.
In vitro, human colon cancer cell lines were treated with anti-CEA MAb IgG1, hMN-14 (labetuzumab), to assess direct effects on proliferation, as well as antibody-dependent cellular cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC). In vivo studies were undertaken in nude mice bearing s.c. (local growth) or i.v. (metastatic model) GW-39 and LS174T human colon cancer grafts, to evaluate the MAb alone and in combination with either CPT-11 or 5-fluorouracil (5FU).
In vitro, labetuzumab did not induce apoptosis, nor did it affect tumor cell proliferation directly or by CDC, but it did inhibit tumor cell proliferation by ADCC. In vivo, labetuzumab did not increase median survival in the GW-39 metastatic model unless the mice were pretreated with GM-CSF to increase their peripheral WBC counts; GM-CSF alone was ineffective. Also, if GW-39 tumors were pretreated with IFN-gamma to up-regulate CEA expression threefold prior to i.v. injection, labetuzumab significantly increased median survival of the mice. When nude mice received labetuzumab with CPT-11 or 5FU, median survival increased significantly as compared to the drug or antibody alone.
Labetuzumab, a CEA-specific MAb, induces effector-cell function in vitro against CEA-positive colonic tumor cells, and also inhibits growth of lung metastasis when CEA expression is up-regulated or if peripheral WBCs are increased. The MAb also shows chemosensitizing properties.
癌胚抗原(CEA,CD66e,CEACAM5)除了作为多种癌症的血液标志物外,其表达升高还与肿瘤形成的多个生物学方面有关,特别是肿瘤细胞黏附、转移、细胞免疫机制的阻断以及具有抗凋亡功能。然而,尚不清楚用抗CEA抗体治疗是否会影响肿瘤转移或改变细胞毒性药物的作用。
在体外,用人抗CEA单克隆抗体IgG1、hMN-14(拉贝妥单抗)处理人结肠癌细胞系,以评估其对增殖的直接影响,以及抗体依赖性细胞毒性(ADCC)和补体依赖性细胞毒性(CDC)。在携带皮下(局部生长)或静脉内(转移模型)GW-39和LS174T人结肠癌移植瘤的裸鼠中进行体内研究,以评估单独使用单克隆抗体以及与伊立替康(CPT-11)或5-氟尿嘧啶(5FU)联合使用的情况。
在体外,拉贝妥单抗不诱导细胞凋亡,也不直接或通过CDC影响肿瘤细胞增殖,但它通过ADCC抑制肿瘤细胞增殖。在体内,拉贝妥单抗在GW-39转移模型中并未增加中位生存期,除非用粒细胞-巨噬细胞集落刺激因子(GM-CSF)预处理小鼠以增加其外周白细胞计数;单独使用GM-CSF无效。此外,如果在静脉注射前用γ干扰素预处理GW-39肿瘤以将CEA表达上调三倍,拉贝妥单抗可显著增加小鼠的中位生存期。当裸鼠接受拉贝妥单抗与CPT-11或5FU联合治疗时,与单独使用药物或抗体相比,中位生存期显著延长。
拉贝妥单抗是一种CEA特异性单克隆抗体,在体外可诱导效应细胞针对CEA阳性结肠肿瘤细胞发挥功能,并且当CEA表达上调或外周白细胞增加时,还可抑制肺转移灶的生长。该单克隆抗体还具有化学增敏特性。